MedTrace Logo

Porphozym in the Treatment of Acute Attacks in AIP

NCT00418795 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-03-09

No results posted yet for this study

Summary

A multi-centre, double-blind, randomized, placebo controlled, parallel group trial, investigating the efficacy and safety of Porphozym (recombinant human porphobilinogen deaminase)in the treatment of acute attacks in AIP.

Conditions

  • Acute Intermittent Porphyria

Interventions

DRUG

recombinant human porphobilinogen deaminase (Porphozym)

Sponsors & Collaborators

  • Zymenex A/S

    lead INDUSTRY

Principal Investigators

  • Christer Andersson, MD · Umeå University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-11
Primary Completion
2006-06-20
Completion
2006-06-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418795 on ClinicalTrials.gov